May 18, 2024
Biodefense Market

Biodefense Market is Expected to be Flourished by Increased Government Biodefense Budgets

Biodefense is the development and utilization of strategic and practical defenses against biological weapons or infectious diseases. The key products and equipment in biodefense include vaccines, antimicrobials, disinfectants, diagnostic kits, ventilators, personal protective equipment, and decontamination systems. Vaccines help in safeguarding civilians and military forces against biological threats caused by infectious pathogens. Antimicrobials refer to drugs that either kill or inhibit the growth of microorganisms such as viruses, bacteria, fungi, or parasites. Disinfectants are chemical compounds that are applied to surfaces and non-living objects to destroy or inhibit the growth of microorganisms. Diagnostic kits are used to identify the presence or absence of specific antigens or antibodies in body fluids or tissues to confirm or rule out infection by specific pathogens. Ventilators are critical care medical devices used in respiratory support for those patients who are unable to breathe properly due to lung failure or weakness. Personal protective equipment includes coveralls, gloves, face masks, respiratory protective devices and protective eyewear for use in clinical settings and during public health emergencies. Decontamination systems are specialized equipment and chemicals used to disinfect or sterilize areas exposed to biological agents in order to render them safe.

The global biodefense market is estimated to be valued at US$ 13.04 Bn in 2023 and is expected to exhibit a CAGR of 7.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:
One major driver for the biodefense market is increased government biodefense budgets. Governments across the globe are allocating higher budgets for biodefense in order to better prepare their countries against potential biological threats. For instance, the US government biodefense budget increased from US$ 7.4 billion in 2020 to US$ 8.1 billion in 2022. The heightened focus on biodefense across nations is prompting increased procurement of protective equipment, diagnostics, vaccines and other biodefense products. Furthermore, growing incidences of infectious diseases are also fueling the biodefense market. According to the World Health Organization, there were over 20 epidemic-prone diseases in circulation in 2020 alone and epidemics are occurring with increased regularity across the world partly due to factors like climate change, population growth and global travel. Diseases such as COVID-19, Ebola, Zika and Anthrax have highlighted the need to build robust biode

Segment Analysis
The global biodefence market can be segmented into vaccines, diagnostics, drugs & pharmaceuticals, protective equipment, and decontamination. The vaccines segment is dominating the market currently due to increasing R&D investments by key players for developing effective biological weapons antidotes. Additionally, supportive government policies are driving vaccine production for countering biological attacks.

PEST Analysis
Political: The biodefense market is witnessing favorable government policies and increased investments for research and preparedness against potential biological threats. However, the use of biological weapons is banned by international treaties.
Economic: The rising GDP and defense budgets of major countries are propelling market growth. However, high R&D costs associated with new product development imposes challenges.
Social: Growing public health awareness and increasing risk perception of biological attacks are propelling demand for biodefense solutions.
Technological: Advancements in fields such as genomics, proteomics, and bioinformatics are facilitating rapid diagnosis and treatment of biological threats. Robust R&D is enabling production of superior vaccines and drugs.

Key Takeaways
The Global Biodefense Market Size is expected to witness high growth.

Regional analysis: North America accounts for over 35% share of the global biodefense market due to supportive government policies and initiatives in the US for research and development of medical countermeasures. For instance, Project BioShield Act provides funding for procurements of medical countermeasures for biodefense.

Key players operating in the biodefense market are ADM, PT Darya-Varia Laboratoria Tbk, Citra Nusa Insan Cemerlang PT, Sido Muncul PT, The Tempo Group, Bayer AG, BASF SE, Pfizer Inc., Natureā‚¬TMs Sunshine Products, Inc., Amway, and Glanbia PLC. Key players such as Pfizer and Emergent Biosolutions are focused on expanding their product portfolios through acquisitions and collaborations.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it